You are here:
| Reference : Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uP... |
| Scientific journals : Article | |||
| Life sciences : Biochemistry, biophysics & molecular biology | |||
| http://hdl.handle.net/2268/63215 | |||
| Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy | |
| English | |
| Frankenne, F. [> > > >] | |
Noël, Agnès  [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >] | |
| Bajou, Khalid [Université de Liège - ULg > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >] | |
| Sounni, Nor Eddine [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >] | |
| Goffin, Frédéric [Université de Liège - ULg > > Gynécologie-Obstétrique CHR >] | |
| Masson, Véronique [Université de Liège - ULg > > Gynécologie-Obstétrique CHR >] | |
| Munaut, Carine [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >] | |
| Remacle, A. [ > > ] | |
| Foidart, Jean-Michel [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement >] | |
| Sep-1999 | |
| Expert Opinion on Therapeutic Targets | |
| Informa Healthcare | |
| 3 | |
| 3 | |
| 469-481 (13) | |
| International | |
| 1472-8222 | |
| London | |
| Uk | |
| [en] angiogenesis ; cancer ; drug ; invasion ; molecular interaction ; therapy ; urokinase plasminogen activator | |
| [en] In the promotion of cancer progression, a classical role had previously been ascribed to the plasminogen activation system on the basis of urokinase plasminogen activator (uPA) proteolytic activity and plasminogen activation triggering a focalised pericellular activation cascade involving matrix metalloproteinases (MMPs). As a result, many pharmaceutical companies have undertaken the development of synthetic uPA inhibitors. However, during the last few years, data have accumulated that uPA, as well as urokinase-type plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1), are likely to play an essential role in tumour progression through non-proteolysis-related activities. Such activities endow them with new and likely key functions in tumour progression-associated events, such as cellular adhesion, migration, invasion and angiogenesis. Since these activities essentially depend upon protein-protein interactions, they represent new therapeutic targets. | |
| http://hdl.handle.net/2268/63215 |
There is no file associated with this reference.
All documents in ORBi are protected by a user license.
